Moore Caroline M, Emberton Mark, Bown Stephen G
Division of Surgical and Interventional Sciences, University College London, London, UK.
Lasers Surg Med. 2011 Sep;43(7):768-75. doi: 10.1002/lsm.21104.
Since the first report of the use of photodynamic therapy (PDT) for prostate cancer in 1990 it has been investigated as a primary and a salvage treatment, using either whole gland or focal approaches. Since 1990 advances in the transperineal approach to the prostate, coupled with photosensitizers which have a short drug-light interval and minimal skin phototoxicity, have resulted in major advances in the field. This review will look at the work done to date, and the ongoing studies which help to define the place of PDT as a useful treatment modality for organ-confined prostate cancer.
自1990年首次报道将光动力疗法（PDT）用于前列腺癌以来，它已被作为一种主要治疗方法和挽救性治疗方法进行研究，采用全腺体或局部治疗方法。自1990年以来，经会阴途径治疗前列腺的技术取得了进展，再加上药物-光照间隔短且皮肤光毒性最小的光敏剂，该领域取得了重大进展。本文将回顾迄今为止所做的工作，以及有助于确定光动力疗法作为器官局限性前列腺癌一种有效治疗方式地位的正在进行的研究。
